Please login to the form below

Not currently logged in
Email:
Password:

Dupilumab

This page shows the latest Dupilumab news and features for those working in and with pharma, biotech and healthcare.

As France protests, Sanofi takes axe to 670 jobs

As France protests, Sanofi takes axe to 670 jobs

dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.

Latest news

More from news
Approximately 4 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Going the distance Going the distance

    Further down the line should come other Regeneron collaborations - first the IL-6 inhibitor sarilumab for rheumatoid arthritis and then dupilumab, which targets the IL-4 pathway that's responsible for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Dr Desiree Luthman joins Verona Pharma Dr Desiree Luthman joins Verona Pharma

    Prior to her new role in Verona Pharma, Luthman previously directed regulatory activities related to pulmonary disease at Sanofi and led its regulatory team through the FDA approval of dupilumab for

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics